Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms

Tariq I. Mughal, Jason Gotlib, Ruben Mesa, Steffen Koschmieder, H. Jean Khoury, Jorge E. Cortes, Tiziano Barbui, Rüdiger Hehlmann, Michael Mauro, Susanne Saussele, Jerald P. Radich, Richard A. Van Etten, Giuseppe Saglio, Srdnan Verstovek, Robert Peter Gale, Omar Abdel-Wahab

Research output: Contribution to journalReview article

Abstract

This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalLeukemia Research
Volume67
DOIs
StatePublished - Apr 2018

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genomics
Systemic Mastocytosis
Calreticulin
Neoplasms
Translational Medical Research
Portugal
Epigenomics
Protein-Tyrosine Kinases
Therapeutics
Education

Keywords

  • CALR
  • CML
  • Cardiotoxicity
  • JAK2 inhibitors
  • MPN
  • Mastocytosis
  • TFR

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. / Mughal, Tariq I.; Gotlib, Jason; Mesa, Ruben; Koschmieder, Steffen; Khoury, H. Jean; Cortes, Jorge E.; Barbui, Tiziano; Hehlmann, Rüdiger; Mauro, Michael; Saussele, Susanne; Radich, Jerald P.; Van Etten, Richard A.; Saglio, Giuseppe; Verstovek, Srdnan; Gale, Robert Peter; Abdel-Wahab, Omar.

In: Leukemia Research, Vol. 67, 04.2018, p. 67-74.

Research output: Contribution to journalReview article

Mughal, TI, Gotlib, J, Mesa, R, Koschmieder, S, Khoury, HJ, Cortes, JE, Barbui, T, Hehlmann, R, Mauro, M, Saussele, S, Radich, JP, Van Etten, RA, Saglio, G, Verstovek, S, Gale, RP & Abdel-Wahab, O 2018, 'Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms', Leukemia Research, vol. 67, pp. 67-74. https://doi.org/10.1016/j.leukres.2018.02.008
Mughal, Tariq I. ; Gotlib, Jason ; Mesa, Ruben ; Koschmieder, Steffen ; Khoury, H. Jean ; Cortes, Jorge E. ; Barbui, Tiziano ; Hehlmann, Rüdiger ; Mauro, Michael ; Saussele, Susanne ; Radich, Jerald P. ; Van Etten, Richard A. ; Saglio, Giuseppe ; Verstovek, Srdnan ; Gale, Robert Peter ; Abdel-Wahab, Omar. / Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. In: Leukemia Research. 2018 ; Vol. 67. pp. 67-74.
@article{035b15012a26459398504cf377d67f01,
title = "Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms",
abstract = "This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.",
keywords = "CALR, CML, Cardiotoxicity, JAK2 inhibitors, MPN, Mastocytosis, TFR",
author = "Mughal, {Tariq I.} and Jason Gotlib and Ruben Mesa and Steffen Koschmieder and Khoury, {H. Jean} and Cortes, {Jorge E.} and Tiziano Barbui and R{\"u}diger Hehlmann and Michael Mauro and Susanne Saussele and Radich, {Jerald P.} and {Van Etten}, {Richard A.} and Giuseppe Saglio and Srdnan Verstovek and Gale, {Robert Peter} and Omar Abdel-Wahab",
year = "2018",
month = "4",
doi = "10.1016/j.leukres.2018.02.008",
language = "English (US)",
volume = "67",
pages = "67--74",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms

AU - Mughal, Tariq I.

AU - Gotlib, Jason

AU - Mesa, Ruben

AU - Koschmieder, Steffen

AU - Khoury, H. Jean

AU - Cortes, Jorge E.

AU - Barbui, Tiziano

AU - Hehlmann, Rüdiger

AU - Mauro, Michael

AU - Saussele, Susanne

AU - Radich, Jerald P.

AU - Van Etten, Richard A.

AU - Saglio, Giuseppe

AU - Verstovek, Srdnan

AU - Gale, Robert Peter

AU - Abdel-Wahab, Omar

PY - 2018/4

Y1 - 2018/4

N2 - This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.

AB - This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.

KW - CALR

KW - CML

KW - Cardiotoxicity

KW - JAK2 inhibitors

KW - MPN

KW - Mastocytosis

KW - TFR

UR - http://www.scopus.com/inward/record.url?scp=85042214146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042214146&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2018.02.008

DO - 10.1016/j.leukres.2018.02.008

M3 - Review article

C2 - 29466766

AN - SCOPUS:85042214146

VL - 67

SP - 67

EP - 74

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -